Search clinical trials for: Placebo / Teneli (Teneligliptin) SU (Sulfonylurea)

Total 54 results

Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Handok Inc.

Completed

Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin

Type 2 Diabetes Mellitus

Korea, Republic of
Handok Inc.

Completed

Tenelia Elderly CGMS Study(TEDDY)

Type 2 Diabetes Mellitus

Korea, Republic of
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Handok Inc.

Recruiting

Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin (TERA 304)

Type 2 Diabetes

Korea, Republic of
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of MP-513 in Patients With Type 2 Diabetes

Type 2 Diabetes

Japan
Handok Inc.

Recruiting

Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin (TERA 305)

Type 2 Diabetes

Korea, Republic of
Mitsubishi Tanabe Pharma Corporation

Completed

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)

Type 2 Diabetes Mellitus

Japan
Yonsei University

Completed

A Randomized, Placebo-controlled Clinical Trial of Teneligliptin as Quadruple Oral Combination Therapy for Type 2 DM After Failure of an Oral Triple Anti-diabetic Regimen

Type 2 Diabetes Mellitus

Korea, Republic of
Candan DOGAN
Ataturk University

Not yet recruiting

The Effect of Sujok Therapy on Symptom Burden and Comfort Level in Patients Undergoing Hemodialysis Treatment

Dialysis; Complications
Mitsubishi Tanabe Pharma Corporation

Completed

Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Eli Lilly and Company

Completed

A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
GlaxoSmithKline

Completed

A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in India

Herpes Zoster

India
Mitsubishi Tanabe Pharma Corporation

Completed

Monotherapy Study of MP-513 in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Novartis Pharmaceuticals

Completed

Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin (ADDONIS)

Type 2 Diabetes Mellitus (T2DM)

France
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy

Herpes Zoster | Herpes Zoster Vaccine

Canada, Spain, Korea, Republic of, United Kingdom, France, Czechia
GlaxoSmithKline

Active, not recruiting

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) Who Had Prior Episode of Shingles

Herpes Zoster

Spain, Panama, Mexico, Russian Federation, Finland, Estonia, Hong Kong, United Kingdom
NYU Langone Health

Recruiting

Safety of the Herpes Zoster Subunit Vaccine in Lupus

Systemic Lupus Erythematosus

United States
Changhua Christian Hospital

Completed

Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas

Type 2 Diabetes Mellitus | Proteinuria
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
University of Colorado, Denver
GlaxoSmithKline

Completed

Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds

Herpes Zoster | Shingles

United States
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes

Type 2 Diabetes Mellitus | Obese

Argentina, Canada, South Africa
GlaxoSmithKline

Completed

Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects

Herpes Zoster

Germany, United States, United Kingdom
Eli Lilly and Company

Completed

A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea (GETGOAL-S)

Diabetes Mellitus, Type 2

United States, Romania, Russian Federation, Germany, Netherlands, Turkey, Bulgaria, India, Taiwan, Czech Republic, Tunisia, Japan, Egypt, Israel, Korea, Republic of, Thailand
Sanofi

Completed

Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin (GetGoal-M-Asia)

Type 2 Diabetes Mellitus

China, Hong Kong, Malaysia, Thailand
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA) (GETGOAL-L-ASIA)

Diabetes Mellitus, Type 2

Philippines, Taiwan, Japan, Korea, Republic of
Lawson Health Research Institute
University of Western Ontario, Canada; Academic Medical Organization of Southwestern...

Completed

Vaginal Estrogen With Pessary Treatment

Quality of Life | Urinary Tract Infection | Vaginal Infection

Canada
PhaseBio Pharmaceuticals Inc.

Completed

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

Type 2 Diabetes Mellitus

United States
Sanofi
Hanmi Pharmaceutical Company Limited

Terminated

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea (AMPLITUDE-S)

Type 2 Diabetes Mellitus

United States, China, Taiwan
Peking University People's Hospital
Peking University First Hospital; Jiangsu Province Geriatric Institute

Recruiting

The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes

Diabetes Mellitus, Type 2 | Severe Insulin Deficient Diabetes

China
Vanderbilt University
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Recruiting

Interventions for Reading Disabilities in NF1

Neurofibromatosis Type 1 | Reading Disability | NF1 | Learning Disability

United States
Janssen Research & Development, LLC

Completed

A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea

Diabetes Mellitus, Type 2

China, Malaysia, Vietnam
Eli Lilly and Company

Terminated

A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, Puerto Rico, Greece, Taiwan
Astellas Pharma Inc

Completed

A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Japan
Chonbuk National University Hospital

Unknown

Efficacy and Safety of Ethanol Extracts of Porphyra Tenera(PTE10) on Promotion of Immunity

Immunity

Korea, Republic of
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

Type 2 Diabetes Mellitus

United States, Bulgaria, Estonia, Hungary, Korea, Republic of, Poland, Romania, Slovakia, Ukraine, United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)

Type 2 Diabetes Mellitus
Sanofi

Terminated

Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea

Type 2 Diabetes Mellitus

China
Janssen Research & Development, LLC

Completed

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

Cardiovascular Diseases | Diabetes Mellitus, Type 2

United States
Massachusetts General Hospital
National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)

Active, not recruiting

Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH)

Chronic Pain

United States
AstraZeneca

Completed

Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP) (HARRP)

Type 2 Diabetes Mellitus

Sweden
Yale University
National Institute on Drug Abuse (NIDA); National Institute on Alcohol Abuse... and other collaborators

Completed

Modeling Stress-precipitated Smoking Behavior for Medication Development

Smoking

United States
Lanzhou Institute of Biological Products Co., Ltd

Completed

A Study to Evaluate the Botulinum Toxin Type A for Injection(HengLi®) in Subjects With Post-stroke Upper Limb Spasticity

Cerebrovascular Accident
Lanzhou Institute of Biological Products Co., Ltd

Unknown

A Study to Evaluate Botulinum Toxin Type A for Injection（HengLi®）for Prophylactic Treatment of Chronic Migraine

Chronic Migraine
Yale University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Does Guanfacine Attenuate Stress-Induced Drinking?

Alcohol Drinking

United States

3

Subscribe